Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth

By Reuters News


Overview

  • Ophthalmic pharma and device firm's Q3 revenue rose 58% yr/yr, beating analyst expectations

  • Adjusted net income for Q3 beat analyst expectations

  • Company raised 2026 sales guidance and gave preliminary 2027 sales outlook of $1 bln


Outlook

  • Glaukos raises 2026 net sales guidance to $775 mln-$785 mln from $680 mln-$700 mln

  • Company introduces preliminary 2027 net sales guidance of $1 bln


Result Drivers

  • PRODUCT LAUNCHES - Co cited iDose TR and Epioxa as key drivers of Q3 growth, per CEO Thomas Burns

  • CORNEAL HEALTH - Corneal Health segment sales more than doubled yr/yr, contributing to overall revenue growth

  • U.S. GLAUCOMA - U.S. Glaucoma segment posted 47% yr/yr sales growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$211 mln

$168.05 mln (14 Analysts)

Q3 Adjusted Net Income

Beat

$28.50 mln

-$5.37 mln (13 Analysts)

Q3 Net Income

$2 mln

Q3 Gross Margin

85.00%

Q3 Adjusted Gross Margin

88.00%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Glaukos Corporation is $198.00, about 9.3% above its October 27 closing price of $181.17


Reuters Recommended Reads

  • Oct 27 - OrthoPediatrics Q3 revenue rises, beats estimates

  • Oct 27 - Pulmonx Q3 revenue beats analyst estimates on US sales growth

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.